 |
Prospector
Profile
2-1-003
|
| |
| Oramed Pharmaceuticals, Inc. |
NAICS |
541710 |
| 2 Elza Street
Jerusalem, Israel 93706 |
Description |
Biotechnology |
| 011 972-54-7909058 |
Employees |
4 |
| http://www.oramed.com/home.html |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-3.2360 |
| |
Assets |
(mil) |
1.9370 |
| |
Liability |
(mil) |
1.4240 |
| |
(for the year ended 2007-08-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Oramed Pharmaceuticals, Inc., posted a net loss of $350,000 for the quarter ended November 30, 2007, compared with a net loss of $77,000 for the same period last year. At November 30, 2007, the Company's balance sheet showed $1,566,00 in total assets, $895,000 in total liabilities and only $671,000 in total stockholders' equity. The Company has an accumulated deficit of $4,829,000 as of November 30, 2007.
|
| |
|
Intellectual Property:
The Company has filed a patent application under the Patent Cooperation Treaty at the Israel Patent Office for "Methods and Compositions for Oral Administration of Proteins" (Patent application no. PCT/IL2006/001019). It has also filed three provisional patent applications in the US Patent and Trademark Office for "Methods and compositions for rectal application for insulin" (Patent application no. 60/924.004); "Methods and compositions for rectal application of proteins" (Patent application no. 60/024.005) and "Method and compositions for oral administration of proteins" (Patent application no. 11/513.343). [SEC Filing 10-KSB 12-12-07]
|
| |
|
Description:
Oramed Pharmaceuticals, Inc., engages in the research and development of innovative pharmaceutical solutions.
|
| |
|
Officers:
Nadav Kidron (Pres. & CEO); Alex Werber (CFO & Treas.); George Drazenovic (Sec.); Miriam Kidron (Chief Medical & Technology Officer; Leonard Sank (Dir.)
|
| |
|
Auditor:
Malone & Bailey PC
|
| |
|
Securities:
Common Stock-Symbol ORMP.OB; OTC BB; 46,034,804 common shares outstanding as of January 11, 2008.
|
| |
| |
| |
| return to main page |
|
|
